Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 179 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.

  • Revenue in GBP (TTM)35.94bn
  • Net income in GBP2.66bn
  • Incorporated1992
  • Employees83.50k
  • Location
    AstraZeneca PLC1 Francis Crick AvenueCAMBRIDGE CB2 0AAUnited KingdomGBR
  • Phone+44 207 304 5000
  • Fax+44 207 604 8151
  • Websitehttps://www.astrazeneca.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
AZN:LSE since
Neogene TherapeuticsAnnounced30 Nov 202230 Nov 2022Announced0.96%--
Neogene Therapeutics IncDeal completed29 Nov 202229 Nov 2022Deal completed1.05%320.00m
TeneoTwo IncDeal completed05 Jul 202205 Jul 2022Deal completed3.31%1.27bn
Data delayed at least 20 minutes, as of Mar 29 2023 16:45 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Lonza Group AG5.48bn1.07bn35.01bn17.49k32.653.7421.926.3916.3416.3483.69142.660.36812.285.95355,722.007.205.308.636.4839.1839.9019.5715.201.2721.610.173128.4115.056.4780.2712.8432.934.94
Bayer AG44.58bn3.65bn49.09bn101.37k13.461.445.,537.603.40-1.114.62-1.4560.8458.988.21-3.040.68765.010.5169--15.107.70315.005.024.50-2.72
GSK plc29.32bn4.26bn58.19bn69.40k12.105.418.061.981.173.838.032.630.42121.723.93422,536.007.076.3911.3110.4267.9869.5516.7815.900.68499.220.675293.3718.74-0.577851.7310.270.5035-9.34
Sanofi SA39.88bn7.35bn110.78bn91.57k15.021.6812.042.786.666.6636.1959.700.36761.555.68495,659.206.825.808.377.0269.8368.4918.5417.001.0569.890.222559.8415.864.6234.5217.282.393.28
Novartis AG41.92bn5.63bn168.20bn101.70k28.843.2616.744.012.912.9121.6625.740.41522.176.44467,801.005.589.097.3211.7771.0170.9813.4423.681.0411.760.319659.94-2.153.60-71.05-1.493.093.79
AstraZeneca plc35.94bn2.66bn171.77bn83.50k64.895.7224.804.781.711.7123.0419.370.43941.294.40430,418.103.262.634.313.6280.1378.997.426.350.68066.810.441187.0718.5314.572,835.716.639.681.13
Roche Holding AG55.76bn10.94bn184.26bn103.61k16.737.3412.043.3015.3615.3678.3235.030.70132.275.65610,743.8015.0016.2125.3125.3370.7571.0721.3822.620.925619.250.441959.330.76433.49-10.837.262.632.74
Novo Nordisk A/S20.87bn6.55bn218.77bn54.39k43.7628.6829.8810.4824.3224.3277.5137.110.81221.293.883,253,250.0025.4829.8351.5858.5883.9283.7631.3832.860.69313.020.23645.8825.689.6416.277.8111.279.57
Data as of Mar 29 2023. Currency figures normalised to AstraZeneca PLC's reporting currency: UK Pound GBX

Institutional shareholders

22.12%Per cent of shares held by top holders
HolderShares% Held
BlackRock Investment Management (UK) Ltd.as of 31 Dec 202275.47m4.87%
Wellington Management Co. LLPas of 31 Jan 202264.15m4.14%
The Vanguard Group, Inc.as of 01 Mar 202353.48m3.45%
Capital Research & Management Co. (World Investors)as of 31 Dec 202235.78m2.31%
BlackRock Fund Advisorsas of 01 Mar 202329.07m1.88%
BlackRock Advisors (UK) Ltd.as of 01 Mar 202321.53m1.39%
GQG Partners LLCas of 01 Mar 202317.83m1.15%
BlackRock Advisors LLCas of 01 Mar 202315.47m1.00%
SSgA Funds Management, Inc.as of 01 Mar 202315.45m1.00%
Schroder Investment Management Ltd.as of 01 Mar 202314.60m0.94%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.